What should you know about TNBC cells?

A pathology laboratory checks a tumour sample for hormone receptors and HER2. In triple-negative breast cancer, all three results are negative or do not show excess HER2. This label describes the tumour's tested features; it does not describe a person's symptoms or character.

Because these cells do not rely on those three signals, hormone-blocking medicines and HER2-targeted medicines are generally not the main options. Other features still matter, including tumour size, lymph-node findings, stage, overall health, and inherited gene results.

Ask for a clear explanation of the pathology report and whether additional testing is needed. Your oncology team may discuss chemotherapy before or after surgery, immunotherapy in selected settings, and PARP inhibitor therapy when a relevant inherited mutation is present. The plan depends on the full clinical picture, not the word TNBC alone.

Contact your cancer team promptly for a new fever, breathing difficulty, chest pain, uncontrolled vomiting, sudden weakness, or worsening redness and drainage from a wound. During treatment, use the contact number provided by your team because some complications need same-day assessment.

Which receptors were tested, and what do the exact results mean? What stage and grade were reported? Is genetic counselling or inherited-mutation testing appropriate? Which treatment sequence fits my findings, and which side effects should I report immediately?